Sepsis or SIRS (systemic inflammatory response syndrome) results from infection, whether bacterial, viral, fungal, or parasitic. According to the CDC, sepsis is the second leading cause of death in non-coronary ICU patients in the U.S. The pathogenesis of sepsis is very complex. Both an innate and acquired immune response to infection interrupts homeostasis with a shift of cytokine expression that increases immunosuppression. In addition, migration of the leukocytes in the inflamed tissues secretes a tissue factor leading to the formation of thrombin, also triggering the release of chemokines and adhesion molecules through endothelial cells. Severe sepsis occurs when hypotension or hypoperfusion to one or more organs leads to organ dysfunction, which, in turn, can cause septic shock, multiple organ dysfunction syndrome (MODS) and death.
MILLIPLEX® Human Sepsis Panel 1 is to be used for the simultaneous quantification of any or all of the following analytes in human serum, plasma and cell / tissue culture supernatant samples: sFAS/TNFRSF6, sFasL, sICAM-1, MIF, PAI-1 (total), sVCAM-1. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Immune Response
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp